Skip to content
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
Archyde

Archyde

  • News
  • World
  • Economy
  • Technology
  • Health
  • Entertainment
  • Sport

Real-Time Oncology Review

FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer

FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer

September 15, 2026 by Dr. Priya Deshmukh - Senior Editor, Health

The U.S.

Categories Health Tags ARROS-1 phase I/II trial, Food and Drug Administration, GSK plc, Jideytro, Nuvalent Inc, Real-Time Oncology Review, ROS1-positive non-small cell lung cancer Leave a comment

Recent Posts

  • TrustLaw Legal Support Empowering CSOs and Social Enterprises Since 2010
  • The “Formula” of Western European Cities: Common Patterns and Trends
  • NYC Mayor Zohran Mamdani Criticized for Handshake with Rudy Giuliani at 9/11 Memorial
  • DMG Blockchain Updates Christina Lake AI Data Center Conversion
  • Functional Administrator Real-time Video
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
© 2026 Archyde — All Rights Reserved. Contact | Privacy Policy